When options for autologous arteriovenous (AV) fistulas have been fully exhausted, AV grafts continue to play an important role in access creation for hemodialysis, offering long-term hemodialysis access that is a better alternative to central vein catheters. The drawbacks of AV grafts are their poor patency, infection and higher cost. Their main advantages are that they are widely available, are easy to create, and mature early. In the context of the “Fistula First” initiative, many patients with low quality veins suffer from fistula failure and non-maturation resulting in prolonged catheter days that would otherwise be prevented by initial creation of an AV graft. Endeavors to improve graft patency include administration of pharmacological agents, changing graft configuration, altering graft biology, and altering the graft surface. In this review, the current status of heparin-bonded AV grafts for hemodialysis is discussed.
BresciaMJCiminoJEAppelKHurwichBJChronic hemodialysis using venipuncture and a surgically created arteriovenous fistula.N Engl J Med1966;275(20):1089–1092
2.
BakerLDJrJohnsonJMGoldfarbDExpanded polytetrafluoroethylene (PTFE) subcutaneous arteriovenous conduit: an improved vascular access for chronic hemodialysis.Trans Am Soc Artif Intern Organs1976;22382–387
3.
National Kidney Foundation.K-DOQI clinical practice guidelines for vascular access: update 2000.Am J Kidney Dis2001;37(1 Suppl 1):S137–S181
4.
United States Renal Data System.2015 USRDS annual data report: Epidemiology of kidney disease in the United States.National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2015http://www.usrds.org/2015/view/Default.aspx. Accessed November 21, 2015.
5.
Vascular Access Work Group.Clinical practice guidelines for vascular access.Am J Kidney Dis2006;48(Suppl 1):S248–S273
6.
ChanMRSanchezRJYoungHNYevzlinASVascular access outcomes in the elderly hemodialysis population: A USRDS study.Semin Dial2007;20(6):606–610
7.
RooijensPPTordoirJHStijnenTBurgmansJPSmet deAAYoTIRadiocephalic wrist arteriovenous fistula for hemodialysis: meta-analysis indicates a high primary failure rate.Eur J Vasc Endovasc Surg2004;28(6):583–589
8.
DemberLMBeckGJAllonMet al;Dialysis Access Consortium Study Group.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.JAMA2008;299(18):2164–2171
9.
ClarkTWCohenRAKwakAet al.Salvage of nonmaturing native fistulas by using angioplasty.Radiology2007;242(1):286–292
10.
Vascular Access Work Group.Clinical practice guidelines for vascular access.Am J Kidney Dis2006;48(Suppl 1):S248–S273
11.
BiuckiansAScottECMeierGHPannetonJMGlickmanMHThe natural history of autologous fistulas as first-time dialysis access in the KDOQI era.J Vasc Surg2008;47(2):415–421discussion 420-421.
12.
StevensonKBHannahELLowderCAet al.Epidemiology of hemodialysis vascular access infections from longitudinal infection surveillance data: predicting the impact of NKF-DOQI clinical practice guidelines for vascular access.Am J Kidney Dis2002;39(3):549–555
13.
Roy-ChaudhuryPWangYKrishnamoorthyMet al.Cellular phenotypes in human stenotic lesions from haemodialysis vascular access.Nephrol Dial Transplant2009;24(9):2786–2791
14.
PalmerSCDi MiccoLRazavianMet al.Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis.Am J Kidney Dis2013;61(1):112–122
15.
OsbornGEscofetXDa SilvaAMedical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.Cochrane Database Syst Rev20084CD002786.
16.
KaufmanJSO'ConnorTZZhangJHet al;Veterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis.J Am Soc Nephrol2003;14(9):2313–2321
17.
DixonBSBeckGJDemberLMet al;Dialysis Access Consortium (DAC) Study Group.Use of aspirin associates with longer primary patency of hemodialysis grafts.J Am Soc Nephrol2011;22(4):773–781
18.
CrowtherMAClaseCMMargettsPJet al.Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial.J Am Soc Nephrol2002;13(9):2331–2337
19.
PisoniRBarker-FinkelJAlloMStatin therapy is not associated with improved vascular access outcomes.Clin J Am Soc Nephrol2010;5(8):1447–1450
20.
SchmitzPGMcCloudLKReikesSTLeonardCLGellensMEProphylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial.J Am Soc Nephrol2002;13(1):184–190
21.
LokCEMoistLHemmelgarnBRet al;Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study Group.Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial.JAMA2012;307(17):1809–1816
22.
KapferXMeichelboeckWGroeglerFMComparison of carbon-impregnated and standard ePTFE prostheses in extra-anatomical anterior tibial artery bypass: a prospective randomized multicenter study.Eur J Vasc Endovasc Surg2006;32(2):155–168
23.
KakkosSKTopalidisDHaddadRHaddadGKShepardADLong-term complication and patency rates of Vectra and IMPRA Carboflo vascular access grafts with aggressive monitoring, surveillance and endovascular management.Vascular2011;19(1):21–28
24.
RiesenfeldJOlssonPSanchezJMollnesTESurface modification with functionally active heparin.Med Device Technol1995;6(2):24–31
25.
LarmOLarssonROlssonPA new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue.Biomater Med Devices Artif Organs1983;11(2-3):161–173
26.
BegovacPCThomsonRCFisherJLHughsonAGällhagenAImprovements in GORE-TEX vascular graft performance by Carmeda BioActive surface heparin immobilization.Eur J Vasc Endovasc Surg2003;25(5):432–437
27.
LinPHBushRLYaoQLumsdenABChenCEvaluation of platelet deposition and neointimal hyperplasia of heparin-coated small-caliber ePTFE grafts in a canine femoral artery bypass model.J Surg Res2004;118(1):45–52
28.
BosiersMDelooseKVerbistJet al.Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results.J Vasc Surg2006;43(2):313–318discussion 318-319.
29.
PeetersPVerbistJDelooseKBosiersMResults with heparin bonded polytetrafluoroethylene grafts for femorodistal bypasses.J Cardiovasc Surg (Torino)2006;47(4):407–413
30.
BattagliaGTringaleRMonacaVRetrospective comparison of a heparin bonded ePTFE graft and saphenous vein for infragenicular bypass: implications for standard treatment protocol.J Cardiovasc Surg2006;4741–47
31.
LindholtJSGottschalksenBJohannesenNet al.The Scandinavian Propaten trial - 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses – a randomised clinical controlled multi-centre trial.Eur J Vasc Endovasc Surg2011;41668–673
32.
Anaya-AyalaJEDaviesMGEl-SayedHFPedenEKNaoumJJEarly Experience With a Novel Hybrid Vascular Graft for Hemodialysis Access Creation in Patients With Disadvantaged Anatomy.J Endovasc Ther2015;22778–785
33.
KasirajanKOutcomes after heparin-induced thrombocytopenia in patients with Propaten vascular grafts.Ann Vasc Surg2012;26802–808
34.
ThakurS1PigottJPComerotaAJHeparin-induced thrombocytopenia after implantation of a heparin-bonded polytetrafluoroethylene lower extremity bypass graft: A case report and plan for management.J Vasc Surg2009;491037–1040
35.
WheatcroftMD1GrecoETseLRoche-NagleGHeparin-induced thrombocytopenia in the presence of a heparin-bonded bypass graft.Vascular2011;19338–341
36.
DavidsonIHackermanCKapadiaAMinhajuddibAHeparin bonded hemodialysis e-PTFE grafts result in 20% clot free survival benefit.J Vasc Access2009;10153–156
37.
Charlton-OuwKMNosratiNMillerCC3rdCooganSMSafiHJAzizzadehAOutcomes of arteriovenous fistulae compared with heparin-bonded and conventional grafts for hemodialysis access.J Vasc Access2012;13163–167
38.
ZeaNMenardGLeLet al.Heparin-bonded polytetrafluorethylene does not improve hemodialysis arteriovenous graft function.Ann Vasc Surg2015Aug6pii: S0890-5096(15): 00598–1
39.
AllemangMTSchmotzerBWongVLChangALakinROWoodsideKJWangJKashyapVSHeparin bonding does not improve patency of polytetrafluoroethylene arteriovenous grafts.Ann Vasc Surg2014;2828–34
40.
ShemeshDGoldinIHijaziJet al.A prospective randomized study of heparin-bonded graft (Propaten) versus standard graft in prosthetic arteriovenous access.J Vasc Surg2015;62115–122
41.
ShemeshDOlshaOBerelowitzDZaghalIZigelmanCZAbramowitzHBIntegrated approach to construction and maintenance of prosthetic arteriovenous access for hemodialysis.Vascular2004;12243–255
42.
ShemeshDGoldinIBerelowitzDZaghalIOlshaOThrombolysis for early failure of prosthetic arteriovenous access.J Vasc Surg2008;47585–590
43.
ShemeshDGoldinIZaghalIBerelowitzDVerstandigAOlsha O Heparin-bonded graft (Propaten) versus standard graft in prosthetic arteriovenous access.J Vasc Access2011; 12161
44.
BaekIHwangJParkJKimHParkJSKimDJPaclitaxel coating on the terminal portion of hemodialysis grafts effectively suppresses neointimal hyperplasia in a porcine model.J Vasc Surg2015;611575–1582
45.
BaekIBaiCZHwangJParkJParkJSKimDJSuppression of neointimal hyperplasia by sirolimus-eluting expanded polytetrafluoroethylene (ePTFE) haemodialysis grafts in comparison with paclitaxel-coated grafts.Nephrol Dial Transplant2012;271997–2004
46.
PerlJWaldRMcFarlanePet al.Hemodialysis vascular access modifies the association between dialysis modality and survival.J Am Soc Nephrol2011;221113–1121
47.
DesilvaRNPatibandlaBKVinYet al.Fistula first is not always the best strategy for the elderly.J Am Soc Nephrol2013; 241297–1304
